Once the person is no longer acutely unwell and have completed at least 7-days of self-isolation.

The Flu vaccine DOES NOT contain or have any element of COVID protection within it.

No there is no gap required between the two vaccinations. The influenza (flu) and COVID vaccines can be given at the same time, before or after each other.

Yes, you can have your Flu Vaccination at the same time as your Covid Vaccinations.

Yes. Any Covid Vaccinations WILL NOT protect you for the Flu. They are two very different vaccines.

Yes absolutely.

Yes, it is still important to have the flu vaccine. The flu is a serious illness that causes hundreds of deaths each winter in New Zealand, and thousands of hospital admissions and doctor’s visits.

As well as saving the lives of the more vulnerable members of our communities, improving our population’s protection against the flu also improves our ability to manage any increased demand on health services as a result of COVID

With the boarders opening shortly, flu will be circulating around. We recommend protecting you and your family by having your annual Flu Vaccination.

If you want to take advantage of the free Flu Vaccinations, we recommend you contact your Family GP, Medical Centre or Doctor’s Surgery to make an appointment. Maxwell Health are not currently able to claim the subsidy from the Ministry of Health to cover the cost of Flu Vaccinations for those who qualify.

Maxwell Health do not carry out Workplace Vaccinations for children or those under the age of 18 years.  We recommend children or young adults under 18 years of age are vaccinated at their Family GP, Medical Centre or Doctor’s Surgery.

The Flu Vaccine is an intramuscular (IM) injection. Our nurse will administer the injection into the deltoid muscle at the top of the arm.

Our nurse will advise each person to wait for 20 mins following the vaccination.

On rare occasions some recipients may encounter an anaphylactic reaction after receiving the injection. It is important that a trained medical professional is on hand to assist if this does take place. If it is going to happen, an anaphylactic reaction usually occurs within 20 minutes of the vaccine being administered.

Minor illness with or without fever doesn’t normally stop you from having your Flu Vaccination. However; with COVID-19 we recommend as per the government guidelines that you stay home and ask your manager for a voucher.

Our vouchers are designed for people that are not able to attend our nurse visit, companies with less than 10 people to vaccinate or companies with remote workers or shift workers (whereby it is more convenient for the individual to attend a nominated Medical Centre/Pharmacy). The voucher is pre-paid and is given to the Medical Centre/Pharmacy in lieu of payment.

Hard copy Flu Vouchers are not able to be replaced once handed out by our nurse or couriered. However; another voucher can be purchased. 

Any Downloadable Vouchers that are emailed out can be resent.

No you can show the Medical Centre/Pharmacy your voucher on your phone. Make sure they record your name, company & the voucher number in their records.

No.

No – blood products are not used in the manufacturing process.

No – the vaccine is preservative free. The vaccine does not contain thiomersal.

The vaccine may contain traces of neomycin and polymyxin as these substances are used in production and are removed in the process, however small amounts may remain.
The vaccine should be used with caution for people with a hypersensitivity to traces of these. However, this vaccine should not be used in people who have had an anaphylactic reaction to neomycin or polymyxin. Vaccine data sheets may vary in their recommendations or contraindications.

Regarding hypersensitivity and contraindications, current best evidence for influenza vaccines and recommendations by IMAC and Australian Society of Clinical Immunology and Allergy (ASCIA) are that individuals with anaphylaxis to any ingredient in the vaccine are contraindicated except egg allergy and should not receive a vaccine that includes them as residual.

The syringes do not contain any latex components. However, the manufacturer is unable to confirm that the product did not come in contact with any latex materials during the manufacturing and packaging process. There is a possibility that the needle cover DOES contain latex. Patients highly sensitive to latex, who have a history of severe hypersensitivity response to this material are advised that they should consult their doctor.

No – The vaccine will only provide protection against the strains of influenza virus present in the vaccine.

No – Anti-virals only help relieve symptoms once you have the flu. Your best prevention method is to get vaccinated.

The optimal time to be vaccinated is in advance of the peak period of influenza activity, usually Autumn (April – June). Influenza vaccines can be given even when influenza virus activity has been identified, as protective antibody levels have been observed to develop from four days to two weeks after immunisation.

Annual immunisation is required for two key reasons: first, because protection lessens over time; second, because, influenza can be caused by different strains of influenza viruses that are not always represented in the previous year’s vaccine.

Seasonal influenza vaccinations are recognised as being the single most effective way of reducing the impact of seasonal influenza – especially for those most at risk of complications.  This can be particularly true for the elderly.

No – The vaccines have been made from influenza virus that has been concentrated, inactivated, then broken apart. It cannot cause influenza as the vaccine does not contain any live viruses.

When vaccinated, the body responds to the vaccine by producing an immune response. This can include systemic symptoms such as fever, malaise and muscle aches. Other respiratory viruses circulate during the winter months and influenza vaccines do not protect against these. Most of these viruses cause milder infections (e.g. the common cold) and do not pose the same threat, particularly to those at higher risk. They should not be confused with influenza. Certain other infections may, on occasion, produce influenza-like symptoms and quite severe illness, which can lead to the suggestion that the vaccine is ineffective.

The seasonal influenza vaccine contains fragments of disrupted (inactivated) virus. It stimulates the immune system to produce antibodies that naturally protect against circulating influenza viruses. Many other viruses are also present throughout the year, so people may catch a different respiratory infection with ‘flu-like’ symptoms around the time the vaccine is given and mistakenly blame the influenza vaccine or influenza virus. The vaccine itself can cause mild aches and pains for up to a day or two after vaccination. Sometimes this is mistaken as early symptoms of the flu.

Everyone, even the fit and healthy. Influenza continues to be a major threat to public health worldwide because of its ability to spread rapidly through populations.

In most cases the vaccine can be safely administered to people with a history of allergy to egg. An individual with an egg allergy that does not result in anaphylaxis can be vaccinated at General Practices, Pharmacies or the Workplace.

If an individual has a high-risk of complications from influenza and has a history of anaphylaxis to eggs, it is important to seek specialist advice about influenza vaccination. The risk of anaphylaxis needs to be considered against the benefits of being protected from influenza or its complications. As the vaccine virus is grown in hens’ eggs it may contain minute amounts of egg protein.

Yes. Sulfonamide (sulfur) antibiotics, such as co-trimoxazole, sulfasalazine, and sulphite preservatives used in food are different to medicines containing the words sulfate or sulphate, e.g. gentamicin sulphate.

The general contraindication to receiving any vaccine is a history of anaphylaxis to a previous dose or any constituent of the vaccine.

Immunisation should be deferred for anyone who is acutely unwell with a fever or other systemic illness.

Influenza vaccine is produced in hen’s eggs and may contain residual egg protein. Patients who have had a confirmed anaphylactic reaction to egg protein can still receive the vaccine under specialist supervision.

Neomycin and polymyxin are also residual in some influenza vaccines and patients with known anaphylaxis to these should not receive a vaccine that includes them as residual.

If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give the vaccine should be based on careful consideration of the potential benefits and risks.

Not a problem at all, whether it be before or after.

Influenza vaccination is approximately 80% effective in preventing infection with influenza A and B viruses in healthy adults under 65 years of age, when there is a good match between the vaccine and circulating influenza strains.

Although older people may have a reduced immune response to influenza vaccine compared with younger adults, they still benefit from influenza vaccination. Older people are more likely to have an associated condition and are more likely to develop complications from influenza

It takes up to two weeks for the vaccine to give full protection.

Effectiveness is reduced by the degree of difference between circulating virus and vaccine strains. The influenza virus does keep changing and new vaccines are formulated for each northern and southern hemisphere season. There may be some cross protection against an influenza virus not in the vaccine.

Protection should last throughout the influenza season and re-immunisation within 12 months is not usually necessary, unless travelling to the northern hemisphere during its peak influenza season. Immunisation is ideally provided in Early autumn (April/May/June), one or two months before the influenza season starts, to ensure that peak protection occurs during the season itself.

Commonly reported adverse events in children (6 months to 5 years of age) fever, appetite loss, irritability and drowsiness; (6 months to 18 years of age) redness and swelling at the injection site. Other common adverse events include headache, myalgia, pain at injection site and fatigue.

Systemic reactions such as fever or aches and pains occur in about 1 in 10 adult vaccinees and are generally mild and of short duration. Children are more likely to experience a fever following influenza vaccine than adults. This is, however normally less than 1 in 10 of vaccinees.

Yes – When the available vaccine gives protection against influenza viruses circulating in the northern hemisphere, travellers – particularly those in ‘high-risk’ groups – who will be exposed to a northern hemisphere influenza season should consider immunisation or re-immunisation prior to travel. Protective antibodies peak one to two months after vaccination and then begin to wane.

At six to eight months after vaccination, protective levels are lower and may not be sufficient to provide good protection. Re-immunisation should be considered where the benefits to the patient outweigh the risks.

All travellers are at risk of contracting influenza during travel. Studies have indicated that influenza is the most commonly caught vaccine-preventable disease amongst international travellers. Influenza outbreaks have been linked to travellers. Certain types of travel, including ship voyages and mass gatherings are particularly high risk. For these reasons, all people travelling outside New Zealand should consider influenza vaccination pre-travel. Those who are in ‘high-risk’ groups and eligible for the subsidised influenza vaccine and who have not yet received the annual influenza vaccine should definitely take the opportunity to have the vaccine. In tropical countries influenza activity can occur throughout the year. In temperate climates in the northern hemisphere activity is more common between the months of December and March.

The United States Advisory Committee on Immunization Practices (ACIP) recommendations are similar and recommend that people at high risk of influenza complications should consider receiving influenza vaccine before travel if they plan to:

a) travel to the tropics;
b) travel with large organised tourist groups at any time of the year (e.g. cruise ships); or
c) travel to temperate climates within the northern hemisphere (e.g. UK) between November and March.

The optimum time is prior to the initiation of chemotherapy or radiation treatment. Following cessation of chemotherapy, normal immune responses return after about 30 days. A medical specialist’s advice should be sought when considering the repeat influenza vaccination of a patient following bone marrow transplantation.

The protective effectiveness of influenza vaccination is likely to be low in this group of patients, thus additional preventative strategies are needed. Hospital-acquired influenza is the most likely route of infection so ‘ringfencing’ of such patients by immunising family members and hospital staff should be considered.

Yes – New Zealand and international experience from previous seasonal influenza outbreaks and the 2009/2010 pandemic showed that pregnant women had significantly more complications associated with influenza illness than other groups. Maternal influenza infection has been associated with an increased risk of maternal hospitalisation, fetal malformation and other illnesses.

There are a range of changes that occur during pregnancy which may put pregnant women at higher risk of complications from influenza. These include changes to the lung function including decreased lung capacity and tidal volume; increased cardiac output and oxygen consumption, and changes to the immune response particularly cell-mediated immunity. Because of the above changes, pregnant women with coexisting medical conditions are at even greater risk of severe influenza-related illness. When pregnancy is superimposed on high-risk conditions such as asthma or diabetes mellitus, influenza infection associated illness is 3-4 times greater than for non-pregnant women.

The seasonal influenza vaccine is strongly recommended for women who will be pregnant during the influenza season. Where possible, vaccines are usually given in the second and third trimesters but because vaccination with the influenza vaccine has been shown to be highly beneficial for pregnant women and their unborn babies, it is recommended that influenza vaccination should be offered to all women who will be pregnant when influenza is circulating. New Zealand is not alone in this recommendation, influenza vaccination for all pregnant women is currently recommended by health authorities in the USA, Australia and many European countries.

The influenza vaccine has been shown to be safe and effective in pregnant women in all trimesters, no unusual patterns in pregnancy or fetal outcomes have been observed in vaccine adverse events reports.

Influenza infection in young infants often prompts hospitalisation and can predispose infants to bacterial pneumonia or otitis media. Another compelling reason to give influenza vaccine to the pregnant woman is the passive protection the mother will pass on to their young infant. Vaccination of pregnant women against influenza has been shown to decrease the incidence of influenza in their new-born babies. Infants of immunised mothers are nearly 50% less likely to be admitted to hospital with influenza than those of unvaccinated mothers.

Yes – The vaccine may be safely given to a lactating woman.